Source: European Medicines Agency (EU) Revision Year: 2019 Publisher: Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands
Trulicity 0.75 mg solution for injection in pre-filled pen.
Trulicity 1.5 mg solution for injection in pre-filled pen.
| Pharmaceutical Form |
|---|
|
Solution for injection (injection). Clear, colourless solution. |
Trulicity 0.75 mg solution for injection:
Each pre-filled pen contains 0.75 mg of dulaglutide* in 0.5 ml solution.
Trulicity 1.5 mg solution for injection:
Each pre-filled pen contains 1.5 mg of dulaglutide* in 0.5 ml solution.
* Produced in CHO cells by recombinant DNA technology.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Dulaglutide |
Dulaglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist. In contrast to native GLP-1, dulaglutide is resistant to degradation by DPP-4, and has a large size that slows absorption and reduces renal clearance. Dulaglutide improves glycaemic control through the sustained effects of lowering fasting, pre-meal and postprandial glucose concentrations in patients with type 2 diabetes. |
| List of Excipients |
|---|
|
Sodium citrate |
Glass syringe (type I) encased in a disposable pen.
Each pre-filled pen contains 0.5 ml of solution.
Packs of 2 and 4 pre-filled pens and multipack of 12 (3 packs of 4) pre-filled pens. Not all pack sizes may be marketed.
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands
EU/1/14/956/001
EU/1/14/956/002
EU/1/14/956/003
EU/1/14/956/006
EU/1/14/956/007
EU/1/14/956/008
Date of first authorisation: 21 November 2014
| Drug | Countries | |
|---|---|---|
| TRULICITY | Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
